VYCO · Vycor Medical Inc · Financials
Substantial doubt about the company's ability to continue as a going concern.
“The Company has incurred losses since its inception, including a net loss of $2,180 for the six months ended June 30, 2026 and has not generated sufficient positive cash flows from operations. As of June 30, 2026 the Company had a working capital deficiency of $4,294,543 which includes related party liabilities of $3,800,538. These conditions, among others, raise substantial doubt regarding our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.4M | $1.46M | $1.36M | $1.2M | $1.33M | $1.61M | $1.68M | $1.8M | $2.18M | — | — | — | — | — | — | — | |
| USD/shares | $0.00 | -$0.01 | -$0.01 | -$0.01 | -$0.02 | -$0.03 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | $0.00 | -$0.01 | -$0.01 | -$0.01 | -$0.02 | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 33.37M | 32.88M | 32.6M | 31.71M | 29.63M | 26.1M | 23.96M | 21.6M | 18.37M | 11.07M | 10.84M | 10.27M | 6.32M | 5.64M | 5.2M |
| shares | — | 33.37M | 32.88M | 32.6M | 31.71M | 29.63M | 26.1M | 23.96M | 21.6M | 18.37M | 11.07M | 10.84M | 10.27M | 6.32M | 5.64M | 5.2M |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current portion of other notes payable | 2026-06-30 | USD 303,674 | 10-Q filed 2026-08-14 |
| Noncurrent notes payable | 2026-06-30 | USD 133,978 | 10-Q filed 2026-08-14 |
| Operating lease liabilities | 2026-06-30 | USD 26,700 | 10-Q filed 2026-08-14 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 47 similar-size Medical Devices companies (of 155 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Vycor Medical Inc | $1,796,070 | $1,515,744 | — | — | — | — |
| Nova Vision Inc | $67,330 | $73,580 | — | — | — | — |
| NovaVision | — | — | $82,006 | $92,074 | $119,385 | $102,483 |
| Vycor Medical | — | — | $1,378,598 | $1,130,915 | $1,273,602 | $1,039,562 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| United States | $1,858,494 | $1,585,644 | $1,453,895 | $1,214,723 | $1,374,770 | $1,125,226 |
| Europe | $4,906 | $3,680 | $6,709 | $8,266 | $18,217 | $16,819 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Vycor Medical Inc | $493,787 | $353,052 | — | — |
| Nova Vision Inc | -$183,878 | -$177,917 | — | — |
| Corporate | -$276,009 | -$184,280 | -$151,846 | -$322,490 |
| NovaVision | — | — | -$191,810 | -$223,351 |
| Vycor Medical | — | — | $383,847 | $239,327 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Vycor Medical Inc | 27.5% | 23.3% | — | — |
| Nova Vision Inc | -273.1% | -241.8% | — | — |
| NovaVision | — | — | -233.9% | -242.6% |
| Vycor Medical | — | — | 27.8% | 21.2% |